Tradewell Hold (531203)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trailing P/E of 9.35 is undemanding if current earnings are repeatable
• ROE of 40.44% shows strong historical return on equity
• Piotroski F-Score of 6/9 points to acceptable basic financial health
• Small market cap of ₹35 Cr leaves room for a genuine niche player to grow if operations turn

Concerns

• Latest quarter is tiny: sales only ₹1 Cr and net profit ₹0 Cr, so operating scale is negligible
• ROCE of -10.68% contradicts the 40.44% ROE; the core operating business does not appear profitable
• 0% sales and profit growth, no dividend, and unknown promoter holding make it hard to value
• P/B of 4.87 is expensive: ₹109.72 per share against book value of ₹22.53

AI Analysis

Let me start with what attracts me: this is a micro-cap consulting business with a trailing P/E of only 9.35, so the market is not asking a huge multiple for its earnings. ROE of 40.44% jumps off the page. But Graham taught me to look behind such ratios. ROCE is negative at -10.68%, which tells me the operating business itself is not earning a decent return; the high ROE is probably coming from something other than core operations. As value investors, we can't build a bridge on such a weak foundation. Sales growth is flat at 0.00%, profit growth is flat, and the latest quarter shows sales of only ₹1 Cr and net profit of ₹0 Cr. That is not a scale that gives me confidence in a durable moat. With a market cap of ₹35 Cr, the entire company is tiny, and the price is sitting at ₹109.72, the top of its 52-week range. I am being asked to pay 4.87 times book value for a business whose book value is only ₹22.53. That is a high price for a company with no dividend and no clarity on promoter holding. The Piotroski F-score of 6/9 is reasonably healthy, but it is not a substitute for understanding the economics. A PEG ratio of 0.02 is meaningless when growth is zero; it only looks cheap if you assume fantastic future growth, and there is no evidence of that. I would rather miss a trade than overpay for an unexplained return. This looks more like a slow-growing, low-quality compounder, or perhaps a special situation, but the data is insufficient. I will keep my pencil down until I see clean operating profits, real revenue growth, and evidence of a competitive advantage. Price can stay at this level or go higher; my discipline stays fixed.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer